'永不止步':新业主如何重塑前基因泰克基地的辉煌——商业期刊报道
'We don't stop': How a new owner is turning around a former Genentech site - The Business Journals
生物技术与制药领域的最新动态
'We don't stop': How a new owner is turning around a former Genentech site - The Business Journals
Lonza Sets Date for 2026 Ordinary General Meeting - TipRanks
Lonza’s Capsules Sale Talks Are Nearing The Finish Line - Finimize
Narrow-Moat Lonza's Long-Term Outlook Driven by Strong Outsourced Drug Manufacturing Demand - Morningstar
Switzerland’s Lonza edges closer to sale of its capsule and health ingredients business - 93.3 The Drive
Lonza still intends to sell its capsules and health ingredients business - Endpoints News
Earnings call transcript: Lonza reports strong 2025 results, stock dips - Investing.com
Lonza Sees Steady 2026 Growth After A Strong 2025 - Finimize
Switzerland's Lonza edges closer to sale of its capsule and health ingredients business - Reuters
Lonza delivers strong profitable growth in 2025 - The Pharma Letter
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - Reuters
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - wkzo.com
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - MSN
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - Global Banking & Finance Review